Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Middle East Respiratory Syndrome Coronavirus: What Do We Know?
Jeanann Sousou, DNP, RN

ABSTRACT
Middle East respiratory syndrome coronavirus is a viral respiratory infection initially reported in the Saudi Arabian peninsula in 2012. This epidemic has crossed from Middle Eastern countries into many European and Asian countries. Recently, the United States and United Kingdom have also been impacted. Although there is very little information about its transmission, it is important for the advanced practice nurse to be updated on the current information provided by the Centers for Disease Control and World Health Organization. This report addresses the risks, symptoms, diagnosis, and implications related to Middle East respiratory syndrome coronavirus.

Keywords: MERS-CoV, Middle East respiratory syndrome, respiratory infection, viral, zoonotic transmission

© 2015 Elsevier, Inc. All rights reserved.

Middle East respiratory syndrome coronavirus (MERS-CoV) is a viral respiratory infection initially reported in the Saudi Arabian peninsula in 2012. Today, it is considered an epidemic, crossing from the Middle Eastern countries of United Arab Emirates, Qatar, and Kuwait into many European and Asian countries. The United States and United Kingdom have also been impacted by the MERS-CoV epidemic. Most recently, and as reported by the World Health Organization (WHO), there have been 699 recorded cases worldwide with varying prognoses, approximately 209 deaths, and the majority of cases occurring in men with a median age of 47 years.

In their 2014 report, “Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus,” the Centers for Disease Control and Prevention (CDC) expressed concern about the suspected high rate of mortality and morbidity among patients infected with MERS-CoV, as evidenced by limited human-to-human transmission, symptomology that mimics other respiratory infections, unknown mode of transmission, as well as lack of proper antiviral medications and vaccination. The virus comes from the coronavirus family that has “...crown-like projections on their surfaces and are among the viruses that cause the common cold.” (p. 56) and other respiratory type syndromes. It has been suggested that this virus is found primarily in bats and camels. Camels are indigenous to the Middle Eastern countries initially impacted. Although exact transmission remains unknown, it is suggested that zoonotic transmission between camels and humans through the respiratory route is a possible cause.

Thus far, in the US there have been two reported cases of MERS-CoV, both occurring in May 2014. The first was reported in Indiana in a man from Saudi Arabia (SA) who both lives and works in the healthcare field in SA. Another person, from Illinois, who was reported to be in contact with the SA visitor, tested positive for MERS-CoV. A second case, similar to the first, was confirmed in a male health-care worker from SA who traveled to Florida. Both patients were admitted, placed in isolation, and discharged after being treated and having been confirmed as no longer a viral threat to the community.

WHO IS AT RISK?
Both CDC (2014) and WHO (2014) have both proposed that recent travelers from the Middle East or Arabian Peninsula are at high risk. They also suggested that those in close contact with someone who either traveled to that region or has somehow been exposed to the virus (ie, camel farm or slaughterhouse) are also at risk. Persons with severe
disease or chronic illness, or who are immunocompromised, are also at increased risk for exposure and infection. These persons should take precautions when traveling to the Middle East or Arabian Peninsula, or when coming in close contact with an infected individual traveling from that region. Precautions should include frequent hand washing, avoiding touching mucous membranes, avoiding any close contact with persons who are ill, and following up on all immunizations about 4 to 6 weeks before travel. WHO suggests that the increase in outbreak in a number of hospital-acquired cases may be related to a lack of proper infection control and prevention measures. Health-care workers should always use standard precautions, specifically droplet precautions in cases of acute respiratory illness of unknown etiology. Presently, CDC and WHO do not advise any special screening or travel restrictions, but only encourage standard precaution and vigilance.

WHAT ARE THE SYMPTOMS AND CLINICAL MANIFESTATIONS OF MERV-COV?

Patients under investigation include those who present with acute respiratory distress syndrome with a fever greater than 100.4°F, and radiographic evidence of consolidation related to parenchymal disease. Patients must also have recently traveled from in or around the Arabian Peninsula within 14 days, have come in close contact with a traveler to that area within the last 14 days, or are from a cluster of patients who demonstrate acute respiratory disease with unknown etiology. Patients are considered susceptible if they present with a fever of greater than 100.4°F and symptoms of respiratory illness with unknown etiology, or had been in a health-care facility within the past 14 days and may have come in close contact with an infected individual. The average incubation period from time of exposure to presence of symptoms is 2 to 13 days, with an average of 5 days.

Patients with MERV-CoV will initially present with pneumonia-like symptoms; however, extreme cases may not only present with acute respiratory distress, but also renal failure, pericarditis, and/or disseminated intravascular coagulation. It is necessary to identify the clinical manifestation of the disease for proper management, because, in rare cases, this disease may rapidly progress to septic shock or fatal multiorgan failure. Common symptomology includes fever, chills/rigor, headaches, nonproductive cough, dyspnea, malagia, and coryza type. Associated gastrointestinal symptoms of diarrhea, nausea, and vomiting may also be present. Low-risk/uncomplicated patients who develop cold-like symptoms were found to recover fairly quickly. Immunocompromised patients, or patients with pre-existing medical conditions, including diabetes, cancers, and chronic lung, heart, or kidney disease, were more at risk for more severe complications, hospitalization, and admissions to the intensive care unit. Although transmission of the disease is time limited, there is currently no research suggesting ongoing spread into the community.

HOW IS THE VIRUS DIAGNOSED?

Confirmation of the virus requires positive polymerase chain reaction on at least two specific genomic targets or a single positive target with sequencing on a second target. Molecular tests are currently being developed to diagnose active infections. Most state labs in the US are approved to test for MERS-CoV by using a real-time reverse transcription polymerase chain reaction assay; however, there is currently no Food and Drug Administration cleared or approved test available in the US. Two consecutive negative real-time reverse transcription polymerase chain reaction assays will confirm the patient as negative for the virus. Serology tests are also conducted in patients suspected to have had a previous infection. The presence of antibodies to MERS-CoV may indicate a previous infection and immunity. Radiographic assessments may rule out other respiratory infections and pneumonia. Laboratory values will demonstrate leukopenia, lymphopenia, thrombocytopenia, and elevated lactic dehydrogenase levels, whereas radiographic images will show either unilateral or bilateral consolidation or patchy densities.

WHO and CDC both advise that lower respiratory tract specimens of sputum, endotracheal aspirate, or bronchoalveolar lavage should be considered when diagnosing patients presenting with the aforementioned symptoms. In patients who are strongly suspected but unable to produce a lower tract specimen or present with suggested symptoms, a nasopharyngeal or oropharyngeal swab should be
obtained. If the results of the swab are negative, a repeat test for confirmation is recommended, as subsequent testing has resulted in positive findings. Stool, serum, and urine samples should be considered, as the virus has been identified in other bodily fluids. Guidelines for collecting, handling, and testing clinical specimens suggested by CDC and WHO can be further reviewed at http://www.cdc.gov/coronavirus/mers/downloads/guidelines-clinical-specimens.pdf and http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_investigation_guideline_Jul13.pdf.

As always, all health-care personnel and employees collecting specimens or in contact with infected patients should wear personal protective equipment, and all standard and droplet precautions must be taken to prevent transmission.

IMPLICATIONS FOR HEALTH-CARE PROVIDERS

CDC has prepared the “Healthcare Provider Preparedness Checklist for MERS-CoV” (www.cdc.gov/coronavirus/mers/downloads/checklist-provider-preparedness.pdf). Patients suspected of having MERS-CoV should be reported immediately to the state or local health department. Care of the patient will include proper and immediate evaluation with cultures, complete blood count, chemistry panel, and radiographic testing. Once confirmed and reported, infection control measures should be taken to protect those in close contact with an affected patient. Standard and droplet precautions should be implemented for all health-care personnel in contact with the infected person. Hospitalization is only required when the infection is accompanied by high fever, pneumonia-like symptoms, renal or liver compromise or immunocompromise, or severe infection. Patients discharged home should remain quarantined with all outside activity restricted.

As this is a new viral infection that is found to be self-limiting, there is currently no antiviral treatment or vaccine. CDC recommends those cleared for discharge home should have their residence assessed to confirm that it is both suitable and appropriate. Isolation measures include separation and restriction of activities of a contagious person from those who are well. The quarantined person should have a designated private bathroom, sleep in a designated private room, and have basic amenities available. If the person lives in a multifamily dwelling, there should ideally be a separate air ventilation system. The primary caregiver for the quarantined individual must be able to assist the ill person with most activities of daily living while also maintaining precautions to be protected from exposure. Patient and caregiver education should include proper hand hygiene, use of a face mask, covering of mouth and nose with the elbow when coughing and sneezing, avoidance of mucous membrane exposure with unwashed hands, avoidance of any personal contact with sick people, and frequent cleaning and disinfecting of touched surfaces. For further information about home care, refer to http://www.cdc.gov/coronavirus/MERS-hcp/home-care-patient.html.

CDC advises that all hospitalized patients conform to standard contact and airborne precautions implemented in the health-care setting with regard to patients diagnosed or highly suspected of having MERS-CoV. CDC recommends hospitalization of any patients who have other conditions and illnesses and who may require additional care. Admitted patients should be placed in an airborne infection isolation room. Personnel should use and personal protective equipment, including gloves, a gown, eye protection, and a National Institute for Occupational Safety and Health–certified filtering face piece respirator or face mask if a respirator is not available. Health-care personnel who believe they have been exposed to a patient with MERS-CoV and develop respiratory symptoms should take the same precautionary measures as previously noted, initiate isolation precautions, and seek immediate medical attention for confirmation. Asymptomatic health-care personnel who believe they have been exposed should be monitored for symptoms for 14 days and protect others by wearing a proper face mask. Further information can be found at http://www.cdc.gov/coronavirus/mers/downloads/MERS-Infection-Control-Guidance-051414.pdf.

At the time this article was prepared (September 29, 2014), both CDC and WHO did not advise any restriction to traveling to the Arabian Peninsula or surrounding countries. However, travel precautions counseling should be incorporated for those planning to go to that region. People are strongly advised to...
remain vigilant in maintaining proper hygienic methods and avoiding contact with those with MERS-CoV. Travelers who suspect they have been exposed to or develop respiratory symptoms within 14 days of exposure should seek immediate medical attention. For further information on travel notices and alerts, refer to the travel advisory page on the CDC website (http://wwwnc.cdc.gov/travel/notices).

**CONCLUSION**

Although this is a fairly new respiratory infection with very little information available, it is important to remain very aware of MERS-CoV symptomology and take all necessary precautions to prevent the disease from spreading.

**References**

1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update. http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1. Accessed September 29, 2014. Published June 11, 2014. Updated June 11, 2014.

2. Todd B. Emerging infections: Middle East respiratory syndrome (MERS-CoV). Am J Nurs. 2014;114:56-59.

3. Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill. 2014;19(16):20781.

4. Centers for Disease Control and Prevention. Middle East respiratory syndrome: MERS in the US. http://www.cdc.gov/coronavirus/MERS/US.html. Published June 20, 2014. Updated June 20, 2014. Accessed September 29, 2014.

5. Centers for Disease Control and Prevention. Middle East respiratory syndrome: people who may be at increased risk. http://www.cdc.gov/coronavirus/MERSrisk.html. Published June 20, 2014. Updated June 20, 2014. Accessed September 29, 2014.

6. Centers for Disease Control and Prevention. MERS in the Arabian Peninsula. Published October 4, 2012. Updated May 21, 2014. http://wwwnc.cdc.gov/travel/notices/watch/coronavirus-saudi-arabia-qatar. Accessed September 29, 2014.

7. Centers for Disease Control and Prevention. MERS clinical features. Updated June 25, 2014. http://www.cdc.gov/coronavirus/mers/clinical-features.html. Published May 22, 2014. Accessed September 29, 2014.

8. World Health Organization. Interim surveillance recommendations for human infection with Middle East respiratory syndrome coronavirus. http://www.who.int/csr/disease/coronavirus_infections/InterimRevisedSurveillanceRecommendations_nCoVInfection_27Jun13.pdf?ua=1. Published June 27, 2013. Updated June 27, 2013. Accessed September 29, 2014.

9. Centers for Disease Control and Prevention. Middle East respiratory syndrome: transmission. http://www.cdc.gov/coronavirus/MERS/about/transmission.html. Published May 16, 2014. Updated May 16, 2014. Accessed September 29, 2014.

10. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention Laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.cdc.gov/coronavirus/MERS/lab/lab-testing.html. Published June 6, 2014. Updated June 6, 2014. Accessed September 29, 2014.

11. World Health Organization. WHO guidelines for investigation of cases of human infection with Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_investigation_guide Jul13.pdf. Published July 2013. Accessed September 29, 2014.

12. Centers for Disease Control and Prevention. Interim guidance for healthcare professionals. http://www.cdc.gov/coronavirus/mers/interim-guidance.html. Published June 12, 2014. Updated July 29, 2014. Accessed September 29, 2014.

13. Centers for Disease Control and Prevention. Interim guidance for preventing MERS-CoV from spreading to others in homes and communities. http://www.cdc.gov/coronavirus/MERS/hcp/home-care-patient.html. Published July 11, 2014. Updated July 11, 2014. Accessed September 29, 2014.

14. World Health Organization. Interim guidance document: clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do. http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf. Published February 11, 2013. Accessed September 29, 2014.

Jeanann Sousou, DNP, RN, CNM-FA is a Certified Nurse Midwife. She is also an Assistant Professor at Rutgers, State University of New Jersey School of Nursing, Camden Campus. She can be reached at Jeanann.sousou.cnm@rutgers.edu. In compliance with national ethical guidelines, this author reports no relationships with business or industry that would pose a conflict of interest.